Should I Buy JYNT? JYNT 2026 Analysis

Should You Buy Joint Corp (JYNT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

9.720

1 Day change

1.36%

52 Week Range

13.470

Analysis Updated At

2026/02/05

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Not a good buy right now (pre-market ~$9.75). Near-term momentum is weak (MACD worsening) and options positioning is heavily bearish (very high put/call OI), which is not ideal for an impatient entry.
Best immediate read: this is more of a “wait/hold” setup until price reclaims $9.85–$10.22 (pivot to R1) with improving momentum; otherwise downside risk toward $9.49 (S1) dominates.
Intellectia Proprietary Trading Signals
- AI Stock Picker: no signal on given stock today.
- SwingMax: No signal on given stock recently.
Positioning/flow checks: Hedge funds and insiders are neutral; no recent congress trading data available.

Technical Analysis

Trend/Momentum: MACD histogram -0.0419 and negatively expanding → bearish momentum building.
RSI: RSI(6) 46.35 → neutral (no oversold bounce signal yet).
Moving averages: Converging MAs → compression/indecision; typically needs a catalyst or breakout to trend.
Key levels (near-term): Pivot 9.853 (current price slightly below/near). Resistance 10.216 (R1) then 10.44 (R2). Support 9.49 (S1) then 9.266 (S2).
Quant pattern read (similar candlesticks): ~80% chance of -0.13% next day, but +3.6% next week and +4.97% next month → near-term chop/weakness with potential medium-term rebound if support holds.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Sentiment: Open interest put/call 12.55 (puts 966 vs calls 77) → strongly defensive/bearish positioning.
Liquidity/confirmation today: Options volume is 0 today → the signal is from positioning (OI), not active intraday flow.
Volatility: 30D IV 58.71 vs historical vol 40.85 → options implying elevated uncertainty; IV percentile ~60.6 (moderately high).
Implication for “buy now”: skewed put positioning + weakening momentum reduces attractiveness for an immediate long entry.

Technical Summary

Sell

Buy

Positive Catalysts

- Medium-term upside case: Pattern-based stats favor gains over the next week/month if $9.49 support holds.
- Operational thesis (from bullish analysts): Refranchising progress could drive margin and free cash flow inflection once completed.
- Profitability quality signal: Gross margin improved to 76.77% (+2.33% YoY).
- Event catalyst ahead: Next earnings QDEC 2025 on 2026-03-04 (after hours) (Est. EPS 0.05).

Neutral/Negative Catalysts

- Bearish momentum: MACD is below zero and deteriorating, increasing odds of a near-term drift lower.
- Demand softness: Reported comps down 2.0% (per analyst commentary) and continued softness in new patient acquisition.
- Options positioning: Extremely high put/call OI (12.55) suggests market participants are positioned defensively.
- No supportive news flow: No recent news catalysts in the past week to spark a breakout.
- Key downside risk: Failure to hold $9.49 (S1) opens room toward $9.27 (S2).

Financial Performance

Latest reported quarter: 2025/Q3.
Revenue: $13.38M, +5.74% YoY → top-line still growing.
Earnings: Net income $0.86M, -127.01% YoY and EPS $0.06, -128.57% YoY → sharp profitability deterioration vs prior year.
Margins: Gross margin 76.77%, +2.33% YoY → unit economics improved, but not translating to bottom-line growth yet.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: Ratings/targets moved more cautious on 2025-11-07 with multiple price target cuts, including a notable downgrade.
B. Riley (2025-11-07): Downgraded to Neutral from Buy; PT $9 (from $18) citing deteriorating trends and “transitional” FY2025.
Lake Street (2025-11-07): Kept Buy; PT cut to $11 (from $16) due to slower-than-expected franchising and soft clinic fundamentals.
Roth Capital (2025-11-07): Kept Buy; PT cut to $14 (from $15), still constructive on margin/FCF inflection post-refranchising.
Wall Street pros vs cons: Pros focus on the refranchising-driven margin/FCF upside; cons focus on near-term demand softness and trend deterioration. Net: mixed, with the most recent actions skewing negative due to lowered targets and one downgrade.

5 Analyst Rating

Wall Street analysts forecast JYNT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JYNT is 11.33 USD with a low forecast of 9 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

3 Hold

0 Sell

Moderate Buy

Current: 9.590

Low

Averages

11.33

High

Current: 9.590

Low

Averages

11.33

High

B. Riley

Buy -> Neutral

downgrade

$18 -> $9

AI Analysis

2025-11-07

Reason

B. Riley

Price Target

$18 -> $9

AI Analysis

2025-11-07

downgrade

Buy -> Neutral

Reason

B. Riley downgraded Joint Corp. to Neutral from Buy with a price target of $9, down from $18. The company's Q3 comps were down 2.0%, reflecting continued softness in new patient acquisition, the analyst tells investors in a research note. The firm Joint's fiscal 2025 as "transitional," as the company tests initiatives and completes refranchising. It cites deteriorating trends for the downgrade.

Lake Street

Ryan Meyers

Buy

downgrade

$16 -> $11

2025-11-07

Reason

Lake Street

Ryan Meyers

Price Target

$16 -> $11

2025-11-07

downgrade

Buy

Reason

Lake Street analyst Ryan Meyers lowered the firm's price target on Joint Corp. to $11 from $16 and keeps a Buy rating on the shares. The transition toward a fully franchised model has taken longer than originally expected, says the analyst, who lowers the firm's price target as the underlying fundamentals at the clinic level remain soft.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for JYNT

Unlock Now

JYNT Should I Buy

JYNT Should I Buy

Should You Buy Joint Corp (JYNT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch